MetaVia’s (MTVA) Buy Rating Reaffirmed at HC Wainwright

MetaVia (NASDAQ:MTVA)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report released on Friday,Benzinga reports. They currently have a $20.00 target price on the stock.

Several other analysts also recently issued reports on MTVA. Weiss Ratings restated a “sell (e+)” rating on shares of MetaVia in a report on Friday, April 24th. Wall Street Zen upgraded MetaVia to a “sell” rating in a report on Saturday, June 20th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, MetaVia currently has a consensus rating of “Hold” and an average target price of $20.00.

MetaVia Price Performance

MetaVia stock opened at $1.73 on Friday. The firm’s 50 day simple moving average is $1.90 and its 200-day simple moving average is $2.66. The company has a market cap of $8.93 million, a P/E ratio of -0.33 and a beta of 0.97. MetaVia has a fifty-two week low of $0.97 and a fifty-two week high of $19.03.

MetaVia (NASDAQ:MTVA) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.03). On average, analysts expect that MetaVia will post -2.78 EPS for the current fiscal year.

Institutional Trading of MetaVia

An institutional investor recently bought a new position in MetaVia stock. Virtu Financial LLC acquired a new stake in MetaVia Inc. (NASDAQ:MTVA) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned 0.14% of MetaVia as of its most recent filing with the SEC. Institutional investors and hedge funds own 1.37% of the company’s stock.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.